These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 29775625)

  • 1. Reduction-sensitive polymeric nanomedicines: An emerging multifunctional platform for targeted cancer therapy.
    Sun H; Zhang Y; Zhong Z
    Adv Drug Deliv Rev; 2018 Jul; 132():16-32. PubMed ID: 29775625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
    Bar-Zeev M; Livney YD; Assaraf YG
    Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unraveling the role of Intralipid in suppressing off-target delivery and augmenting the therapeutic effects of anticancer nanomedicines.
    Islam R; Gao S; Islam W; Šubr V; Zhou JR; Yokomizo K; Etrych T; Maeda H; Fang J
    Acta Biomater; 2021 May; 126():372-383. PubMed ID: 33774199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peptide-decorated polymeric nanomedicines for precision cancer therapy.
    Sun H; Dong Y; Feijen J; Zhong Z
    J Control Release; 2018 Nov; 290():11-27. PubMed ID: 30290243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Copolymers of poly(lactic acid) and D-α-tocopheryl polyethylene glycol 1000 succinate-based nanomedicines: versatile multifunctional platforms for cancer diagnosis and therapy.
    Vijayakumar MR; Muthu MS; Singh S
    Expert Opin Drug Deliv; 2013 Apr; 10(4):529-43. PubMed ID: 23316695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Actively targeted nanomedicines for precision cancer therapy: Concept, construction, challenges and clinical translation.
    Gu W; Meng F; Haag R; Zhong Z
    J Control Release; 2021 Jan; 329():676-695. PubMed ID: 33022328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymeric nanomedicine for cancer MR imaging and drug delivery.
    Khemtong C; Kessinger CW; Gao J
    Chem Commun (Camb); 2009 Jun; (24):3497-510. PubMed ID: 19521593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer Nanomedicines Based on Synthetic Polypeptides.
    Sun H; Gu X; Zhang Q; Xu H; Zhong Z; Deng C
    Biomacromolecules; 2019 Dec; 20(12):4299-4311. PubMed ID: 31659901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-targeted nanomedicines for cancer theranostics.
    Arranja AG; Pathak V; Lammers T; Shi Y
    Pharmacol Res; 2017 Jan; 115():87-95. PubMed ID: 27865762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction-responsive polymers for drug delivery in cancer therapy-Is there anything new to discover?
    Monteiro PF; Travanut A; Conte C; Alexander C
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2021 Mar; 13(2):e1678. PubMed ID: 33155421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanomedicines for advanced cancer treatments: Transitioning towards responsive systems.
    van Elk M; Murphy BP; Eufrásio-da-Silva T; O'Reilly DP; Vermonden T; Hennink WE; Duffy GP; Ruiz-Hernández E
    Int J Pharm; 2016 Dec; 515(1-2):132-164. PubMed ID: 27725268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What Went Wrong with Anticancer Nanomedicine Design and How to Make It Right.
    Sun D; Zhou S; Gao W
    ACS Nano; 2020 Oct; 14(10):12281-12290. PubMed ID: 33021091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction-responsive polymeric micelles and vesicles for triggered intracellular drug release.
    Sun H; Meng F; Cheng R; Deng C; Zhong Z
    Antioxid Redox Signal; 2014 Aug; 21(5):755-67. PubMed ID: 24279980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors affecting toxicity and efficacy of polymeric nanomedicines.
    Igarashi E
    Toxicol Appl Pharmacol; 2008 May; 229(1):121-34. PubMed ID: 18355886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using Peptide Aptamer Targeted Polymers as a Model Nanomedicine for Investigating Drug Distribution in Cancer Nanotheranostics.
    Zhao Y; Houston ZH; Simpson JD; Chen L; Fletcher NL; Fuchs AV; Blakey I; Thurecht KJ
    Mol Pharm; 2017 Oct; 14(10):3539-3549. PubMed ID: 28880092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Robust and smart polypeptide-based nanomedicines for targeted tumor therapy.
    Deng C; Zhang Q; Guo J; Zhao X; Zhong Z
    Adv Drug Deliv Rev; 2020; 160():199-211. PubMed ID: 33137364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Classification of stimuli-responsive polymers as anticancer drug delivery systems.
    Taghizadeh B; Taranejoo S; Monemian SA; Salehi Moghaddam Z; Daliri K; Derakhshankhah H; Derakhshani Z
    Drug Deliv; 2015 Feb; 22(2):145-55. PubMed ID: 24547737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymeric nanomedicines as a promising vehicle for solid tumor therapy and targeting.
    Gupta M; Agrawal GP; Vyas SP
    Curr Mol Med; 2013 Jan; 13(1):179-204. PubMed ID: 22834834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-Targeted Nanomedicine for Immunotherapy.
    Cabral H; Kinoh H; Kataoka K
    Acc Chem Res; 2020 Dec; 53(12):2765-2776. PubMed ID: 33161717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.